The association of T lymphocytes and dendritic cells with the stromal mononuclear cell response to basal cell carcinomas has led to speculation that cellular immunity may, in part, regulate the growth and development of this neoplasm. It has not been established, however, whether these T cells are functionally competent, or simply coincidental bystanders. We examined the immunologic phenotypes of mononuclear cells in 32 lesions of basal cell carcinoma obtained from 26 patients. The majority of infiltrating mononuclear cells were T cells that were equally distributed between the helper/inducer (Leu 3a+) and cytotoxic/suppressor (Leu 2a+) subtypes; a minority of cells were dendritic and expressed Leu 6 antigen. Virtually all T cells and dendritic cells were HLA-DR+, and many (>30 %) of the T cells expressed antigens consistent with stages of ongoing activation (T9, T10). TS2/7, a novel monoclonal antibody recently documented to identify activation-specific subcomponents of 210/165/130 kD glycoprotein complex present on the surface of mitogen-or alloantigen-stimulated human T cells, was also used. Greater than 50% of the T cells observed were TS2/7+. These observations provide in situ immunomorphologic evidence of stromal T cell activation in association with basal cell carcinomas, and suggest a role for active and ongoing cellular immune mechanisms as a determinant of local biological behavior of this neoplasm.
The association of T lymphocytes and dendritic cells with the stromal mononuclear cell response to basal cell carcinomas has led to speculation that cellular immunity may, in part, regulate the growth and development of this neoplasm. It has not been established, however, whether these T cells are functionally competent, or simply coincidental bystanders. We examined the immunologic phenotypes of mononuclear cells in 32 lesions of basal cell carcinoma obtained from 26 patients. The majority of infiltrating mononuclear cells were T cells that were equally distributed between the helper/inducer (Leu 3a+) and cytotoxic/suppressor (Leu 2a+) subtypes; a minority of cells were dendritic and expressed Leu 6 antigen. Virtually all T cells and dendritic cells were HLA-DR+, and many (>30 %) of the T cells expressed antigens consistent with stages of ongoing activation (T9, T10). TS2/7, a novel monoclonal antibody recently documented to identify activation-specific subcomponents of 210/165/130 kD glycoprotein complex present on the surface of mitogen-or alloantigen-stimulated human T cells, was also used. Greater than 50% of the T cells observed were TS2/7+. These observations provide in situ immunomorphologic evidence of stromal T cell activation in association with basal cell carcinomas, and suggest a role for active and ongoing cellular immune mechanisms as a determinant of local biological behavior of this neoplasm.
A number of recent studies have focused on the in s itu association of va rious subsets of lymphocytes, identified by immunologic methods, with cuta neous alterations typical of a variety of inflammato ry dermatoses and cutaneous neoplas m s [1] [2] [3] [4] [5] . The immunologic phenotypes of t hese cell s (e.g., helper/ inducer subset) provide litt le informatio n , however, concerning t heir actual-state func t ional compete ncy [6] [7] [8] [9] . Recently, monoclonal antibodies have been developed t hat defin e glycoproteins essentially restricted, at extra t hymic sites, to activated T cells [10] . Detection of these activation antigens may be expected to provide in sight into t he functional capacity a nd responsiveness of mononuclear ce lls infiltrating the s kin.
The role of local cellular immunity in basal cell carcinoma has been t he s ubject of seve ra l recent investigations [11] [12] [13] [14] .
Manuscrip t rece ived .Janu ary 14, 1985 In order to determine whether T cells associated with basal cell carcinomas express activation a n t igen s, we studied 32 lesions from 26 patients with a panel of monoclonal a n tibodies, including OKT9, OKT10, a nd TS2/7. OKT9 recognizes t he transferrin receptor [ 15, 16] of proliferating cells, a nd h as been sh own to identify T cells in early phases of activation, before t he onset of DNA synthesis [6] . OKT10 recognizes a 46 kD antigen [ 15, 17] t hat is expressed during the intermediate stage ofT -cell activation [6] . TS2/7 is a newly described monoclonal antibody that reacts onl y with activation-specific subcompon en ts of a glycoprotein complex (A-1A5) found on the surfaces of mitoge n-or a lloan t ige n-stimulated T cells [10, 18] . Our data suggest t h at many T cells ch aracterist ic of t he inflammatory infilt rates of basal cell carcinomas express activation a n tigens and therefore are likely to b e participants in an on going local cuta neou s immune response. The potential significan ce of these observations in regard to t he indolent biologic behavior of these neoplasms is discussed.
MATERIALS AND METHODS

Patient Popu.lation
Thirty-two excisions were obtained from 26 patients who presented for dermatologic evaluat ion as outpatients. All specimens were obtained from sun -exposed sites and all patients had histori cal evidence of longstanding sun exposure. No patients had pigmentary abno rmalit ies, evidence of basal cell nevus sy ndrome, or ove rt immunologic ab normali ties. Detailed clinical questionnaires were maintained and included inform ation releva nt to skin type, sun exposure, and biologic aggressiveness of lesions (size, ulceratio n, rapidi ty of growth). Clinical photographs were obtained in t he majori ty of patients. Specimens were froze n immediately in OCT (Optimal Cutting Temperature; Lab-Tek, Division of Miles Laboratories, Naperv ille, Illinois) and subsequently sectioned on a cryostat for diagnostic evaluation and immunohistochemica l stain ing.
Monoclonal Antibodies
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The monoclonal antibodies Leu 2a, Leu 3a, and ant i-HLA -DR. (Becton Dickenson, Mountain View, California) were used for routine immunop henotyping. Leu 2a reacts with T lymphocytes of t he cytotoxic/suppressor subset, Leu 3a reacts with T lymp hocytes of the helper/ inducer subset, Leu 6 reacts with Langerhans cells and indeterminate cells [19, 20 ] but not wit h peripheral T cells, and ant i-HLA-DR reacts with the nonpolymorphic region of human !a-l ike antigens. In addi t ion, OKT9, OKT10 (Ortho Pharmaceutical, Raritan, New Jersey), and TS2/7 (co urtesy of Steven J. Burakoff, M.D.) , were used to assess stages of T -cell activation in 7 specimens. OKT9 rea cts with the transferrin receptor [1 5,16] and is first observed during early stages of T-cell activation 
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been desc ribed previously in detail [21] . All sections were stained wit h 3,3' -di amin obenzidine (DAB) (Sigma, St. Louis, Missouri) for 60 s and rinsed in phosphate-buffered saline to terminate the sta ining reaction. Sections were counterstained lightl y with methyl gree n prior to observation by light. mi croscopy.
Quantification of Positive Cells
Beca use so me va riabili ty resul ted from regional differences in adjace nt secti ons of tiss ue, rel ative ce ll numbers were determined semiqu antitatively as perce ntages of total mononuclear ce ll number. Enumeratio n of positive ly labeled cells we re fac ilitated by the use of an ocul ar grid mi crometer.
RESULTS
Clinica ll y, 5 cases were biologically agg ressive (large, rapidly growing lesions). There was not correlation, however, between histology , includin g mi totic rate, or immunohi stoc hemical staining patterns and clinical parameters of biologic aggressiveness or of duration of les ions. Histologic eva luation revealed a ll lesions to be invasive basal cell carcinomas. Although some a lso · showed associated multipl e superficial foci within the epidermis, sclerosing or anaplastic (metatypical) variants were not observed.
The majority (>90%) of mononuclea r cells in the stromal infiltrates were reactive with either anti-Leu 2a or anti-Leu 3a a ntibodies. On the ave rage , approximately 50% were Leu 2a+ a nd 50 % were Leu 3a+, with a range of 40-60 % in individua l cases (Fig lA ,B) . All o f these cells expressed HLA-DR a ntigen (Fig l C ) , as dete rmin ed by qua ntitative evaluation of adjacent sections. T cell s were int imately assoc iated with tumor cell s co mprising bot h invasive nests a nd mult iple superficial foci. Infiltration of t umor nests by T cells was foca lly observed, pa rt icularly by cells of the Leu 2a+ phenotype. Leu 6+ / HLA -DR+ dendritic ce lls were presen t in normal to apparently inVol. 85, No. 3 creased numbers within t he perilesional epidermis. Similar numbers of dendritic cells were prese nt within t he tumor stroma a nd t he tumor nests (Fig lD ) . The dendrites of these cell s frequently were elaborate and surrounded adjacent epithelial cells, forming an apparent intercellular staining pattern focally within the epidermis and tumor nests (Fig lE) .
Discrete fo ci of OKT9 -a nd OKTlO-positive mononuclear cell s were observed in the stroma l infiltrates. These cells often comprised >30 % of the mononuclear cells in these regions and were associated with tumor nests (Fig 2A,C) , but not wi th perilesional epidermis. Basal cell carcinoma cells at t he periphery of invasive nests a lso stained wi t h OKT9 (Fig 28 ) . Variable staining of mononuclear cells with TS2/7 was observed, and TS2/7+ cells comprised >50% of numerous stromal foci ( Fig  2D) . In addition , stain ing of vessel walls a nd smooth muscle as previously reported [7) , was also observed. This pattern of reactivity facilitated the morphologic definition of the vascular stroma characteristic of basal cell carcinoma and of adjacent normal s kin (report in preparation) .
DISCUSSION
We have demonstrated that subpopulations of stroma l T cells associated with basal cell carcinomas express antigens indicative of various stages of their function a l activation. These data extend previous observation s of immunologic phenotypes of mononuclear cells infiltrating these neoplas ms [11 ,14] , and provide add itiona l evidence for an ongoing local immune response.
Basal cell carci nomas a re characterized by relatively indolent growth, and only rarely metastasize [22] . Aggressive biologic behavior appears to be related to size and growth characteristics of lesions, or defects in immunologic status in certain individuals [23, 24] . Defective local immunosurveilla nce has been suggested to play a role in t he genesis of these tumors in young individua ls prone to multiple lesions [25] . In addition, morphologic and immunohistochemical studies have documented the association of activated lymp hoid cells with cutaneous tumors 
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that may be characterized by clinical regression , such as ma lignant melanoma [4, 26] . It is reaso nable to hypothesize that if T cells are involved in a chronic respon se to local cuta neous (tumo r-related) a ntige ns, they would cycle asynch'ronously at various stages of functi ona l activation. Such functional subpopulations wou ld express glycoproteins common to many act ivated T cell s (e.g., HLA -DR), and s maller proportions of ce lls wou ld demonstrate ma rkers for specific phases (early, intermediate, and late stages) of activation. Our findings are in keeping wit h this notion, a nd provide the first evidence, to our know ledge , of the ex iste nce of various stages ofT -cell activation in inflammatory infiltrates assoc iated with basal cell carcinomas. It is reaso nable that such cell s may pl ay a role in a chronic immunologic respon se to a slowly evolving tumor such as basal ce ll carcinoma.
It is importa nt to recognize t hat establishment of T -cell subtypes has little meaning if t hese cells do not also show ev idence of ongoing fun ctional activation. The use of monoclonal antibodies such as OKT9, OKTlO, a nd TS2/7 should faci litate t he study of activation profiles of cutaneous T -ce ll infiltrates in a variety of disorders. TS2/7 ap pears to be a marker fo r long-term activation of T cell s. This antibody is reactive on ly with T cells among activated hematopoietic cells, and t herefore is more spec ific forT -ce ll activation t ha n monoclonal antibodies such as OKT9 and HLA-DR. T his specificity is similar to that of the interleukin 2 (IL-2) receptor. The level of t h e IL-2 receptor antige n , however, has been reported to dim inish contemporaneously with the expression of TS2/7 antigen [10] , and the latter may t herefore represe nt an eve n more sensitive probe for T cell -spec ific activation.
T cells expressing activation antigens were often in close proxi mity to tum or nests, and were assoc iated with T6+ and HLA-DR+ dendritic cell s. The epithelial cells situated at the periphery of many tumor nests showed reactivity for OKT9, suggesting t hat these cells may be predominantly responsible fo r growth a nd proli feration within these nests.
The precise role of activated T ce lls in t he biologic behavior of cu t aneous tumors cannot be dete rmined from this study. In vi tro assays ex ist, howeve r, for t he measurement of specific alloantige n -like a nd mitoge nic stimul atory effects of norm al and n eoplastic ce ll s on subsets of mononuclea r cell s [27] . Likewise, assays fo r effects of these mononuclear cell s on cultured tumor cell lines have recently been described [27, 28) . Use of t hese techniques is necessary to establish the precise nature of the interaction between activated T ce lls and the neoplastic cells composing cutaneous tumors.
In summary, we desc ribe the presence of several activation antigens on T cells composing the inflammatory infiltrates of basal cell carcinomas. It is suggested that t hese functionally activated cells , along wi t h similarly responsive dendritic antige n-presenting cells, may in part be responsible for the indolent clinical behavior of these tumors. Further in situ studies in immunocompromised hosts prone to t he development of multiple a nd aggressive basal cell carcinomas, and in vitro investigations using models to assess T cell/tumor cell interactions, are indicated to further elucidate t he role of local immunity in these neoplasms.
